---
title: "Aditxt (ADTX) news: reverse split and delisting"
url: "https://aibio.space/companies/aditxt/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ADTX reverse split, delisting, convertible notes, Nasdaq notice and merger news: Aditxt plans 1-for-27 reverse stock split effective May 18. Aditxt, Inc."
---

ADTX Aditxt, Inc. OTC · United States

# Aditxt (ADTX) news ADTX reverse split, delisting and convertible notes news

Mergers · 2026-10-15

## [Aditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal](https://aibio.space/news/aditxt-unit-ignite-proteomics-copley-acquisition-corp-end-spac-merger/)

Aditxt's subsidiary Ignite Proteomics and the blank-check company Copley Acquisition Corp ended their June 2026 business combination agreement on October 9, 2026. Each side bears its own expenses, and the 8-K gives no reason for the termination.

## Latest Aditxt news

1. 2026-10-07 Listings [Nasdaq files to remove Aditxt common stock from listing](https://aibio.space/news/nasdaq-files-remove-aditxt-common-stock-listing/) The Nasdaq Stock Market has filed a Form 25 to remove Aditxt's common stock from listing, dated October 7, 2026. The form does not say why Nasdaq acted, and the company reported $268,852 of cash at March 31, 2026.
2. 2026-09-17 Listings [Nasdaq to delist Aditxt common stock after June suspension](https://aibio.space/news/nasdaq-delist-aditxt-common-stock-after-june-suspension/) The Nasdaq Stock Market said on September 17, 2026 that it will delist the common stock of Aditxt, Inc. The stock was suspended on June 25, 2026 and has not traded on Nasdaq since then.
3. 2026-08-12 Company Updates [Aditxt completes sale of Pearsanta to MDNA Holdings](https://aibio.space/news/aditxt-completes-sale-pearsanta-mdna-holdings/) Aditxt, Inc. said that on August 12, 2026 MDNA Holdings Inc. acquired substantially all of the outstanding shares of its majority-owned subsidiary, Pearsanta, Inc. Pearsanta agreed to pay Aditxt royalties on Net Revenue and two milestone payments of $250,000 each.
4. 2026-07-16 Debt Financing [Aditxt amends secured note purchase deal at Ignite Proteomics](https://aibio.space/news/aditxt-amends-secured-note-purchase-deal-ignite-proteomics/) Aditxt signed Amendment No. 2 to its secured note purchase agreement with Ignite Proteomics investors on July 16, 2026. The amendment adds an investor, cancels one note and issues two new notes, and leaves the total senior secured principal unchanged.
5. 2026-06-22 Debt Financing [Aditxt adds $769,230.77 in senior secured convertible notes](https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/) Aditxt sold $769,230.77 of additional senior secured convertible notes for $500,000.00 in cash, and it reported $268,852 of cash at March 31, 2026. The filing does not name the investors.
6. 2026-06-09 Mergers [Aditxt signs deal to take Ignite Proteomics public at $150 million value](https://aibio.space/news/aditxt-signs-deal-take-ignite-proteomics-public-150-million-value/) Aditxt, Inc. signed a definitive business combination agreement for Ignite Proteomics, LLC, its 100%-owned subsidiary, at an implied equity value of approximately $150 million. Ignite would become an independent public company through a newly formed holding company.
7. 2026-06-03 Debt Financing [Aditxt issues senior secured convertible notes with 35% discount](https://aibio.space/news/aditxt-issues-senior-secured-convertible-notes-35-percent-discount/) Aditxt has issued senior secured convertible notes that combine about $725,000 in new cash with earlier notes consolidated into them, at a 35% original issue discount. The company held $268,852 in cash at March 31, 2026.
8. 2026-05-27 Listings [Nasdaq letter says Aditxt falls below $2,500,000 equity minimum](https://aibio.space/news/nasdaq-letter-says-aditxt-falls-below-2-500-000-equity-minimum/) Aditxt, Inc. received a Nasdaq letter on May 27, 2026 citing stockholders' equity of $(35,174,386) for the period ended March 31, 2026. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 11, 2026.
9. 2026-05-14 Listings [Aditxt plans 1-for-27 reverse stock split effective May 18](https://aibio.space/news/aditxt-plans-1-27-reverse-stock-split-effective-may-18/) Aditxt, Inc. said it will effect a 1-for-27 reverse split of its common stock at the opening of trading on May 18, 2026. The company says the split is primarily intended to bring it into compliance with Nasdaq's minimum bid price requirement.
10. 2024-11-15 Distress [Aditxt delays quarterly report for period ended September 30, 2024](https://aibio.space/news/aditxt-delays-quarterly-report-period-ended-september-30-2024/) The company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.

## Aditxt at a glance

- **Ticker**: ADTX

- **Listing**: OTC

- **Country**: United States

- **Cash, Mar 31, 2026**: $268,852

### Related companies

- [Shattuck Labs](https://aibio.space/companies/shattuck-labs/) NASDAQ: STTK
- [United Therapeutics](https://aibio.space/companies/united-therapeutics/) NASDAQ: UTHR
- [TuHURA Biosciences](https://aibio.space/companies/tuhura-biosciences/) NASDAQ: HURA
- [Calithera Biosciences](https://aibio.space/companies/calithera-biosciences/) OTC: CALA
- [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR
- [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS
- [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) NASDAQ: COYA
- [Instil Bio](https://aibio.space/companies/instil-bio/) NASDAQ: TIL

### Also on OTC

- [Abpro Holdings](https://aibio.space/companies/abpro/) ABPO
- [Target Group](https://aibio.space/companies/target/) CBDY
- [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTLC
- [Functional Brands](https://aibio.space/companies/functional-brands/) MEHA
- [CBD Life Sciences](https://aibio.space/companies/cbd-life-sciences/) CBDL
- [PONIARD PHARMACEUT](https://aibio.space/companies/poniard-pharmaceut/) PARD

## What Aditxt does

Aditxt, Inc. is a Delaware corporation headquartered in Mountain View, California. Its subsidiary Adimune, Inc. leads its immune modulation therapeutic programs. Adimune's proprietary Apoptotic DNA Immunotherapy (ADI) is a nucleic acid-based approach designed to induce tolerance to specific tissues, with the aim of prolonging the survival of transplanted organs and reducing the need for immune suppression. Its first candidate, ADI-100, is designed to tolerize against glutamic acid decarboxylase, an antigen implicated in type-1 diabetes, psoriasis and autoimmune diseases of the central nervous system. All preclinical studies for ADI-100 have been completed. The ADI technology is licensed exclusively from Loma Linda University. Adimune has a clinical trial agreement with the Mayo Clinic, and a human trial in Stiff Person Syndrome is expected to get underway in 2026 with enrollment of 10-20 patients. Clinical trials planned in Germany are being managed by a contract research organization. Another subsidiary, Pearsanta, is pioneering molecular tests based on mitochondrial DNA for early cancer detection.

| Product or program | What it is | Stage |
|---|---|---|
| ADI-100 | Immune tolerance DNA therapy targeting GAD for autoimmune diseases | Preclinical studies completed; human trial expected to begin in 2026 |
| Pearsanta molecular tests | Mitochondrial DNA-based molecular tests for early cancer detection |  |

Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/ea0283141-10k_aditxt.htm).

## Aditxt annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$3,195](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) | [$133,985](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) |
| Research and development | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) | [$10.9 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) |
| Net income (loss) | [-$43.1 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) | [-$40.4 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) |
| Cash from operations | [-$25.7 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) | [-$16.8 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026037529/) |
| Cash and equivalents | [$3.2 million](https://www.sec.gov/Archives/edgar/data/1726711/000121390026059562/) | [$833,031](https://www.sec.gov/Archives/edgar/data/1726711/000121390025044298/) |

Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $268,852.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Aditxt

Did Aditxt do a reverse stock split?

Our latest story on this, dated May 14, 2026: "Aditxt plans 1-for-27 reverse stock split effective May 18". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aditxt-plans-1-27-reverse-stock-split-effective-may-18/).

Was Aditxt delisted?

Our latest story on this, dated Oct 7, 2026: "Nasdaq files to remove Aditxt common stock from listing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-files-remove-aditxt-common-stock-listing/).

Has Aditxt sold convertible notes?

Our latest story on this, dated Jun 22, 2026: "Aditxt adds $769,230.77 in senior secured convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aditxt-adds-769-230-77-senior-secured-convertible-notes/).

Has Aditxt received a Nasdaq deficiency notice?

Our latest story on this, dated Nov 15, 2024: "Aditxt delays quarterly report for period ended September 30, 2024". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aditxt-delays-quarterly-report-period-ended-september-30-2024/).

Is Aditxt involved in a merger or acquisition?

Our latest story on this, dated Oct 15, 2026: "Aditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/aditxt-unit-ignite-proteomics-copley-acquisition-corp-end-spac-merger/).

What is the ticker symbol of Aditxt?

Aditxt, Inc. trades under the ticker ADTX on OTC.

Where is Aditxt listed?

Aditxt, Inc. is listed on OTC.

What is the SEC CIK of Aditxt?

The SEC Central Index Key (CIK) for Aditxt, Inc. is 1726711. Its filings are on SEC EDGAR.

How many shares does Aditxt have outstanding?

815,921 shares as of 2026-05-20, per the cover page of its 10-Q filed 2026-05-20.

Which country or territory is Aditxt listed under?

Our directory records Aditxt, Inc. under United States.

What does Aditxt do?

Our directory classifies Aditxt, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Aditxt?

The ISIN recorded for Aditxt, Inc. is US0070258696.

Does aibio.space cover Aditxt?

aibio.space lists Aditxt, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Aditxt incorporated?

SEC records list its state or country of incorporation as DE.

What does Aditxt develop?

Aditxt, Inc. is a Delaware corporation headquartered in Mountain View, California. Its subsidiary Adimune, Inc. leads its immune modulation therapeutic programs.

## Investor discussion: Aditxt

Members talk about Aditxt (ADTX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Aditxt, newest first. Each line links the filing it comes from.

1. 2026-10-15 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026109826/ea0308693-8k_aditxt.htm)
2. 2026-10-07 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000135445726000962/xslF25X02/primary_doc.xml)
3. 2026-09-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026102469/ea030577601ex99-1.htm)
4. 2026-07-17 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026079025/ea0298348-8k_aditxt.htm)
5. 2026-06-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026071380/ea029578801ex99-1.htm)
6. 2026-06-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026067421/ea029430701ex99-1.htm)
7. 2026-05-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm)
8. 2026-05-22 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026060588/ea0292057-pre14a_aditxt.htm)
9. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026057810/ea0290622-nt10q_aditxt.htm)
10. 2026-05-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026057811/ea029070701ex99-1.htm)
11. 2026-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026053904/ea0289662-8k_aditxt.htm)
12. 2026-05-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026050995/ea0288779-8k_aditxt.htm)
13. 2026-04-03 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026039987/ea0284875-def14a_aditxt.htm)
14. 2026-04-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026038906/ea0284653-8k_aditxt.htm)
15. 2026-03-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026035644/ea0283831-424b5_aditxt.htm)
16. 2026-03-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026033647/ea0283212-pre14a_aditxt.htm)
17. 2026-03-13 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026027281/ea027944301ex99-1.htm)
18. 2026-03-05 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026023888/ea028006301ex99-1.htm)
19. 2026-02-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026016565/ea0277129-8k_aditxt.htm)
20. 2026-01-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026010217/ea0274881-8k_aditxt.htm)
21. 2026-01-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390026008539/ea0274343-8k_aditxt.htm)
22. 2025-12-16 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025122329/ea0269766-def14a_aditxt.htm)
23. 2025-12-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025121306/ea0269074-424b5_aditxt.htm)
24. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025118750/ea0268358-8k_aditxt.htm)
25. 2025-11-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025111244/ea0265950-nt10q_aditxt.htm)
26. 2025-10-31 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025104704/ea026328501ex99-1_aditxt.htm)
27. 2025-10-20 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025100380/ea0261857-8k_aditxt.htm)
28. 2025-09-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025091128/ea0258643-8k_aditxt.htm)
29. 2025-08-27 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025081146/ea0254726-8k_aditxt.htm)
30. 2025-08-08 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1726711/000121390025073708/ea0252389-def14a_aditxt.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:ADTX on TradingView](https://www.tradingview.com/symbols/OTC-ADTX/).

## SEC filings and registration

- **SEC name**: Aditxt, Inc.

- **CIK**: 1726711

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ADTX (OTC)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 737 N. FIFTH STREET, SUITE 200, RICHMOND, VA, 23219

- **Phone**: 909-488-0844

- **Shares outstanding**: 815,921 as of 2026-05-20 (10-Q filed 2026-05-20)

- **Former names**: ADiTx Therapeutics, Inc.; Aditx Therapeutics, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026109826/ea0308693-8k_aditxt.htm) filed 2026-10-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026102469/ea0305776-8k_aditxt.htm) filed 2026-09-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026091703/ea0302612-8k_aditxt.htm) filed 2026-08-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026079025/ea0298348-8k_aditxt.htm) filed 2026-07-17
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026071380/ea0295788-8k_aditxt.htm) filed 2026-06-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026071119/ea0295502-8k_aditxt.htm) filed 2026-06-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026067421/ea0294307-8k_aditxt.htm) filed 2026-06-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1726711/000121390026066823/ea0293812-8k_aditxt.htm) filed 2026-06-09

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001726711), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Aditxt, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker ADTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Aditxt, Inc.

- **Ticker**: ADTX

- **Listing**: OTC

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US0070258696

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-ADTX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/aditxt/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Aditxt (ADTX) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/aditxt/